Management of Cardiovascular Disease Bleeding

Initial Assessment and Management

The American College of Cardiology recommends immediately classifying the bleeding as major or non-major to guide management approach, with major bleeding defined as critical site bleeding, hemodynamic instability, hemoglobin drop ≥2 g/dL, or requiring ≥2 units of packed RBCs 1, 2
The American College of Cardiology suggests discontinuing all anticoagulants and antiplatelet agents immediately, securing airway if compromised, and establishing large-bore intravenous access for volume resuscitation, although this specific recommendation is from Praxis Medical Insights, a similar recommendation is found in 2
Obtain laboratory tests including PT/INR, aPTT, and specific anticoagulant activity measurements when available, as recommended by the American College of Cardiology 2

For patients with mechanical valves and uncontrollable bleeding, the American College of Cardiology recommends administering 4-factor prothrombin complex concentrate (or its activated form) 4
Consider adjunctive intravenous vitamin K if resumption of VKA therapy is not anticipated for 7 days, as suggested by the American College of Cardiology 4
For dabigatran-related bleeding, the American College of Cardiology recommends administering idarucizumab 4
For factor Xa inhibitor-related bleeding (rivaroxaban, apixaban, edoxaban), the American College of Cardiology suggests administering andexanet alfa 4

For non-functioning or unneeded CVADs with associated thrombosis, remove the catheter after initiating anticoagulation, as recommended by the American Journal of Kidney Diseases and Blood advances 5, 6
Delay removal for a few days after starting anticoagulation to reduce risk of embolic events, as suggested by Blood advances 6, 7

Transfuse packed red blood cells to maintain hemoglobin ≥7 g/dL (≥8 g/dL in patients with coronary artery disease), as recommended by Praxis Medical Insights, although a similar recommendation may be found in other sources 3
Consider anti-fibrinolytic agents such as tranexamic acid in cases of persistent bleeding, as suggested by Praxis Medical Insights, although a similar recommendation may be found in other sources 3

Patients with cardiovascular disease have higher mortality risk from bleeding events than those without cardiovascular disease, as reported by the American College of Cardiology 2

Avoid using PT/INR alone to monitor direct Xa inhibitors as these tests have important limitations, as warned by the American College of Cardiology 2
Do not administer intravenous vitamin K rapidly in patients with mechanical heart valves due to risk of valve thrombosis, as cautioned by Praxis Medical Insights, although a similar warning may be found in other sources 3

Reassess the need for anticoagulation after bleeding is controlled, as recommended by Praxis Medical Insights, although a similar recommendation may be found in other sources 3
For patients with mechanical heart valves who experience thromboembolism while on therapeutic anticoagulation, consider increasing INR target or adding low-dose aspirin after bleeding is controlled, as suggested by the American College of Cardiology 4